Related Experiment Video
Updated: Jan 29, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Statins and the risk of bleeding in patients taking dabigatran
Bo-Lin Ho1,2, Ya-Ju Lin3, Sheng-Feng Lin4
1Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Insights
For patients with non-valvular atrial fibrillation (NVAF) on dabigatran etexilate, concurrent statin use was linked to a significantly lower risk of bleeding complications. This suggests statins may enhance safety when used with this anticoagulant.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Dabigatran etexilate is a direct thrombin inhibitor for stroke prevention in non-valvular atrial fibrillation (NVAF).
- Statins are widely used for cardiovascular disease prevention.
- The safety of co-administering statins with dabigatran etexilate is not well understood.
Purpose of the Study:
- To evaluate the safety and persistence of dabigatran etexilate when co-prescribed with statins.
- To assess the bleeding risk in NVAF patients on dabigatran and statins.
Main Methods:
- Prospective, multicenter registry study.
- Inclusion of NVAF patients initiating dabigatran therapy after ischemic stroke (2013-2017).
- Primary outcome: symptomatic bleeding at 90, 180, and 360 days.
Main Results:
- 652 patients (336 statin users, 316 non-users) were followed for 1 year.
- Statin users exhibited a significantly lower bleeding risk (adjusted hazard ratio: 0.11, P < 0.001).
- Higher bleeding-free survival rates were observed in patients prescribed statins (P = 0.028).
Conclusions:
- Co-prescription of statins with dabigatran etexilate is associated with reduced bleeding risk in NVAF patients undergoing secondary stroke prevention.
- Further research is warranted to elucidate the underlying pharmacological mechanisms.
- This finding suggests a potentially safer therapeutic strategy for NVAF patients requiring anticoagulation and statin therapy.
Objectives:
Dabigatran etexilate is a direct thrombin inhibitor that clinicians increasingly prescribe to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). Clinicians also commonly prescribe statins for primary and secondary prevention of cardiovascular diseases. Little is known about the bleeding risk in patients taking a statin and dabigatran together. The aim of this study was to evaluate the safety and persistence of dabigatran after co-medication with statins.
Materials And Methods:
We performed a prospective, multicenter registry study of stroke patients with NVAF who initiated dabigatran therapy within 3 months after a clinically evident ischemic cerebrovascular event between 2013 and 2017. The main outcome measure was symptomatic bleeding after 90, 180, and 360 days.
Results:
In total, 652 patients (336 statin users, 316 non-users) were followed for 1 year after dabigatran therapy. Cox multivariate analysis demonstrated that male sex, prior use of aspirin, and concurrent use of an antiarrhythmic drug were associated with a higher risk of bleeding at 360 days. After adjusting time-dependent covariates, statin users had a significantly lower bleeding risk (adjusted hazard ratio: 0.11, P < 0.001) than non-users. Kaplan-Meier analysis indicated that patients prescribed with statins had a higher rate of bleeding-free survival (P = 0.028).
Conclusion:
For secondary prevention of stroke in patients with NVAF who are taking dabigatran etexilate, co-prescription with a statin was associated with a lower risk of bleeding complications. Future research is needed to determine the pharmacological mechanism underlying this effect.
Related Concept Videos
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Relative Risk
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Design Example: Analyzing Capacity Contours for Flood Risk Assessment
Patient-centered Care

